• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
High purity nutritional supplement R-lipoic acid powder
Alpha lipoic acid powder
Chromloong
Alphasil Columns
AlphaHybrid Columns
Marsil Columns

Lupin gets US FDA approval for Penicillamine Tablets

expresspharmaDecember 02, 2020

Tag: lupin , FDA , Penicillamine Tablets , Wilson’s disease , cystinuria

Lupin has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis  who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP (RLD: Depen) had an annual sales of approximately $4 million in the US (IQVIA MAT September 2020).

Previous:The Biden effect on India Pharma Inc

Next:Glenmark gets tentative approval from US FDA for Axitinib Tablets, 1 mg and 5 mg

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Lupin gets US FDA approval for Penicillamine Tablets | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Lincomycin HCL (FDA)

Lincomycin HCL (FDA)
Lupeol-98%-Lupinus Albus Extracts

Lupeol-98%-Lupinus Albus Extracts
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Ribavirin (FDA)

Ribavirin (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Mitomycin ( FDA)

Mitomycin ( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service